Coherus Oncology, Inc. (CHRS) Form 10-Q — Aug 5, 2026

$CHRSForm 10-QFiled Aug 5, 2026, 5:14 PM ET0001104659-26-091262Original filing

Coherus Oncology reported Q2 2026 net revenue of $14.3 million, up roughly 40% year over year, driven by LOQTORZI sales of $13.6 million as the PD-1 inhibitor gains volume in nasopharyngeal carcinoma. The loss from continuing operations narrowed to $33.3 million from $44.9 million a year ago on lower R&D and SG&A spend, with Q2 EPS from continuing operations at -$0.22 versus -$0.39.

Key figures

Eps: -$0.13 Q2 2026 total; -$0.22 continuing operations (vs -$0.39 prior year)
Revenue: Q2 2026 net revenue $14.307M (vs $10.254M Q2 2025); 1H 2026 $26.617M (vs $17.853M)
Guidance: Expects 2026 net revenue from continuing operations to be higher than 2025 on continued LOQTORZI growth
Net Income: Q2 2026 net loss $20.631M; continuing operations loss $33.347M (vs $44.862M prior year)
Total Debt: $37.2M 2029 Term Loan (8.0% + 3-month SOFR, matures May 8, 2029); $14.8M net revenue participation liability
Revenue Yoy: +40% Q2 YoY; +49% 1H YoY
Total Assets: $191.2M
Cash Position: $105.3M cash, cash equivalents and marketable securities at 6/30/2026 ($82.9M cash + $22.4M investments)
Shares Outstanding: 154,500,966 as of July 31, 2026 (up 27.5% from 121,154,925 at 12/31/2025)
Atm remaining: $64.9M under TD Cowen Sales Agreement
Junshi royalty: low twenty percent range on LOQTORZI net sales
Option repricing: 8,907,542 options repriced to $1.59; $6.3M incremental stock comp
Feb 2026 offering: 32,890,000 shares at $1.75/share; $53.6M net proceeds
Accumulated deficit: $1.44B
Stockholders equity: $60.8M
Gross margin q2 2026: 70%
Udenyca earnout at risk: $75.0M total (2 x $37.5M payments; thresholds of $300M and $350M net sales not met as of 6/30/2026)
Loqtorzi q2 2026 revenue: $13.6M (+37% YoY)
Junshi milestones remaining: $355.0M
Operating cash burn 1h 2026: $120.0M (vs $72.5M prior year)

Price after filing

1 day: 0.0%7 days: -20.9%30 days: -7.4%

Close on the filing date to close N calendar days later (from $1.48). Historical, not a forecast.

AI analysis

Red flags9 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.